Introduction
============

Obesity is an increase in the body fat mass defined by a body mass index (BMI) \>30 kg/m^2^. This disease has emerged as a major public health problem worldwide, affecting populations from developed and developing countries. In 2016, there were \>650 million adults and 124 million children and adolescents with obesity in the world.[@b1-dmso-12-257] In Brazil, 11.9 million men and 18.0 million women were obese in 2014.[@b2-dmso-12-257] Clinically severe or morbid obesity is characterized as BMI ≥35 kg/m^2^ with at least one obesity-related comorbidity (such as type 2 diabetes, metabolic syndrome, and hypertension); or BMI ≥40 kg/m^2^.[@b3-dmso-12-257] It affects 0.64% (0.46--0.86) of men and 1.6% (1.3--1.9) of women in the world.[@b2-dmso-12-257] This extreme BMI causes a substantial increased risk for comorbidities and mortality, lowering the life expectancy of the patients in 6.5--13.7 years.[@b1-dmso-12-257],[@b2-dmso-12-257],[@b4-dmso-12-257]

The etiology of obesity is multifactorial, caused by an interaction of environmental factors with many variants of minor effect in multiple genes; however, rare monogenic forms caused by mutations with major effect in a single gene were also identified.[@b5-dmso-12-257] Among the monogenic types of nonsyndromic obesity, mutations in *melanocortin 4 receptor gene* (*MC4R*) are considered the most common cause of this disorder (OMIM\*155541).[@b6-dmso-12-257] *MC4R* variations have an autosomal co-/dominant model of inheritance, with a high degree of expressivity and penetrance.[@b5-dmso-12-257]

*MC4R* gene is localized on chromosome 18q21.3. It spans \>1.6 kb and its only one exon encodes a 332 amino acid G-protein-coupled seven-transmembrane-domain receptor. MC4R is expressed in several areas of the brain, including the hypothalamus, which has an important role on food intake and body weight regulation. Activation of MC4R by α-melanocyte-stimulating hormone increases satiety signaling in the brain and decreases appetite.[@b7-dmso-12-257],[@b8-dmso-12-257] In this context, the dysfunctions of MC4R result in hyperphagia and early-onset obesity, making it a potential drug target for the treatment of obesity.[@b9-dmso-12-257],[@b10-dmso-12-257]

In addition, activation of central nervous system melanocortin pathway appears to contribute to the development of hypertension in obese subjects.[@b11-dmso-12-257] Rodents with hypertension have reduced arterial pressure when *MC4R* was blocked, despite exhibiting hyperphagia and obesity.[@b12-dmso-12-257] Furthermore, acute central administration of MC4R agonist increased blood pressure and heart rate.[@b13-dmso-12-257] In humans, MC4R-deficient individuals showed lower blood pressure, heart rate, and prevalence of hypertension when compared to controls. This study also showed that MC4R agonist increases the blood pressure in overweight and obese subjects. These higher levels were sustained during the 7 days of the drug's administration.[@b14-dmso-12-257] All these findings suggest that *MC4R* has an important role in regulating not only the energy balance but controlling the blood pressure as well.[@b15-dmso-12-257]

Epidemiologic data have estimated that 0.05% individuals have variations in *MC4R* in general population.[@b16-dmso-12-257],[@b17-dmso-12-257] Furthermore, the prevalence of *MC4R* variants in adult with obesity is 0.2% and \~5%--6% in patients with severe early-onset obesity.[@b18-dmso-12-257],[@b19-dmso-12-257] However, the prevalence of these mutations varies according to the ethnic composition of the population studied.[@b20-dmso-12-257] Currently, data available regarding rare genetic variants in *MC4R* gene and their associations with monogenic obesity in the Brazilian population are limited. Therefore, the aim of this study was to determine the prevalence of *MC4R* variants in a cohort of severely obese adults, which developed obesity during the childhood or adolescence/youth. We also investigated the phenotype--genotype correlation within *MC4R* variant carriers.

Materials and methods
=====================

Study population
----------------

This study comprised 157 unrelated individuals (71.1% female and 22.9% male), aged 18--65 years (median of age, 36.0 \[28.0; 43.0\]), from Rio de Janeiro, southeast of Brazil. The selection criteria were severe/morbid obesity (BMI ≥35 kg/m^2^ with at least one obesity-related comorbidity or BMI ≥40 kg/m^2^) with childhood onset (0--11 years) or adolescence/youth onset (12--21 years). The period of onset was self-reported. The exclusion criteria were pregnancy; lactation; the use of medication to lose or gain weight; and the presence of known symptoms suggestive of obesity-related syndromes. The cohort was divided in two groups according to the age of onset. The first group comprised 97 patients with childhood-onset obesity and the second group comprised 60 patients with adolescence/youth-onset obesity. All participants were recruited from a nongovernmental organization, called Rescue Group to Self-Esteem and Citizenship of the Obese (in Portuguese, "Grupo de Resgate à Autoestima e Cidadania do Obeso"). Those patients are candidates to undergo bariatric surgery in Brazil. The study was carried out according to the Declaration of Helsinki (1964) and the protocol was approved by Ethics Committee of the Oswaldo Cruz Foundation. All participants have consented to participate and provided written informed consent prior to their inclusion in this study.

Biochemical, anthropometric, and blood pressure measurements
------------------------------------------------------------

The measurement of height, body weight, and waist and hip circumferences was made according to classical methods.[@b21-dmso-12-257] Briefly, waist circumference was evaluated at the midpoint between the iliac crest and the last costal arch and hip circumference was measured at the level of the greater trochanters. BMI and waist--hip ratio (WHR) were then calculated for each participant.

Glucose, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), and triglyceride (TG) were measured by oxidase-peroxidase method (BioSystems), after an overnight fast. C-reactive protein was evaluated using latex agglutination method and hemoglobin glycated was measured by turbidimetric inhibition immunoassay. Low-density lipo-protein cholesterol (LDL-c) was calculated by Friedewald formula (LDL-c = TC -- HDL-c -- TG/5). Participants using medication for these biochemical parameters had their levels excluded from statistical analysis. We also measured blood pressure with the subject seated using wrist blood pressure monitor. Hypertension was diagnosed by blood pressure ≥140 × 90 mm Hg, or use of antihypertensive drug therapy.[@b22-dmso-12-257] In addition, we also used the new classification, in which adults with blood pressure ≥130 × 80 mm Hg are considered having stage 1 hypertension.[@b23-dmso-12-257] Additional information was obtained from patients with pathogenic *MC4R* variants, including dietary intake; physical activity; binge eating assessment; and insulin, leptin, and ghrelin measurements. This information was obtained as described by Magno et al.[@b21-dmso-12-257]

Screening of *MC4R* gene
------------------------

Genomic DNA was extracted from peripheral blood using QIAamp Blood Kit (Qiagen, Valencia, CA, USA). The coding region of *MC4R* gene was screened using Sanger automatic sequencing. These regions were amplified using two sets of custom-designed primers with Primer3Plus software ([Table S1](#SD1-dmso-12-257){ref-type="supplementary-material"}). Reactions were carried out in a total volume of 10 µL, which included 10--20 ng of genomic DNA, 1 unit of AmpliTaq Gold (Thermo Fisher Scientific, Waltham, MA, USA), 1× AmpliTaq buffer, 0.2 mmol/L of each DNTP, 0.3 pmole of each primer, and 2 mmol/L MgCl~2~. Amplification of the first set of primers was performed under following conditions: 95°C for 10 minutes, followed by 35 cycles of 94°C for 1 minute, 60°C for 1 minute, and 72°C for 1 minute; then an elongation step of 72°C for 10 minutes. For the second set of primers, the only difference was in the annealing temperature step, which was 62°C. Amplicons were visualized on 1.5% agarose gels and purified using Sweep Clean up kit (Thermo Fisher Scientific).

The products of PCR were directly sequenced using Big Dye Terminator kit v.3.1 on 3730xl DNA analyzer (Thermo Fisher Scientific). Reactions were carried out in a final volume of 10 µL, containing 10--40 ng of PCR products, 1× sequencing buffer, 1.0 µL Big Dye, and 0.32 pmole of primer. The sequencing of products was performed by following conditions: 40 cycles of 94°C for 10 seconds, 50°C for 5 seconds, and 60°C for 4 minutes. DNA sequences were analyzed and aligned with the reference sequence provided by the National Center for Biotechnology Information (Accession number: NM_005912.2) using the software SeqScape version 2.1 (Thermo Fisher Scientific). Detected *MC4R* mutations were confirmed by bidirectional sequencing of a second PCR reaction.

Bioinformatic tools
-------------------

*MC4R* genomic, transcript, and protein sequences were obtained through the National Center for Biotechnology Information (<https://www.ncbi.nlm.nih.gov/>) and Ensembl database (<http://www.ensembl.org/>). The pathogenicity of variants was evaluated using Polyphen (Polymorphism Phenotyping) and SIFT (Sorting Intolerant From Tolerant) softwares and interpreted according to current standards and guidelines.[@b24-dmso-12-257] Additionally, open reading frames (ORFs) were explored using prediction interface in ORFinder (<https://www.ncbi.nlm.nih.gov/orffinder/>).

Statistical analyses
--------------------

Descriptive statistics were expressed as median (IQR 25%--75%) and n (%). Mann--Whitney and chi-squared tests were used to compare quantitative and qualitative variables, respectively. *P*-value \<0.05 was considered statistically significant. Data were analyzed using SPSS statistical package (IBM Corporation, Chicago, IL, USA).

Results
=======

Basic characteristics of study population
-----------------------------------------

Subject characteristics from the 157 patients are shown in [Table 1](#t1-dmso-12-257){ref-type="table"}. No differences of anthropometric, biochemical, and blood pressure measurements were observed between the categorized groups.

Prevalence of MC4R variants in Brazilian adults with severe obesity
-------------------------------------------------------------------

A total of five variants were detected, including one silent variant (Ile98=), three missense mutations (Ser36Thr, Val103Ile, and Phe202Leu), and one start codon mutation (Met1?) ([Table 2](#t2-dmso-12-257){ref-type="table"}). The electropherogram of these variants is shown in [Figure 1](#f1-dmso-12-257){ref-type="fig"}. Two of those alterations (Val103Ile and Ile98=) are common polymorphisms. All individuals, except one participant, were heterozygous for the five variants. Two patients were compound heterozygous (Ile198=/Phe202Leu and Met1?/Val103Ile). In silico prediction was performed in order to evaluate the impact of these variants on MC4R. The effect of the Ser36Thr, Val103Ile, and Phe-202Leu variants was reported as "Benign" and "Tolerated" by Polyphen and SIFT, respectively. Nevertheless, Met1? variant was predicted to be "deleterious" and "benign" by SIFT and Polyphen, respectively. The potential impact of this variant was also interpreted according to current standards and guidelines, which suggested that variant is pathogenic.[@b24-dmso-12-257] To evaluate the impact of this mutation on MC4R synthesis, we have also analyzed the potential effect on ORFs using NCBI Bioinformatic tools. This analysis suggested that this variant impacts on original ORF, resulting in a second ORF that starts 8 amino acids (24 nucleotides) later.

Phenotype--genotype correlation within MC4R variant carriers
------------------------------------------------------------

A comparison of missense variants frequency (Ser36Thr, Val103Ile, and Phe202Leu) in patients with childhood vs adolescence/youth-onset obesity did not show any signifi-cant differences (3.1% vs 4.2%; *P*=0.651). Of these three mutations, two were specific for patients with childhood-onset obesity (Ser36Thr and Phe202Leu) and one was found in both groups (Val103Ile). The prevalence of Val103Ile polymorphism was higher in patients with adolescence/youth-onset obesity (4.2%) than in childhood-onset obesity (2.1%); however, this result was not significant (*P*=0.277).

We compared the anthropometric, biochemical, and blood pressure measurements, and the presence of hypertension among the carriers (n=10) and noncarriers (n=147) for the identified missense mutations. Our results showed that carriers had higher median WHR (0.99 \[0.96; 1.05\], n=10) than non-carriers (0.97 \[0.92; 1.00\], n=146) (*P*=0.048). No differences were found between the groups in biochemical and blood pressure measurements. We also observed that these missense variants were associated with hypertension (*P*=0.014) ([Table S2](#SD2-dmso-12-257){ref-type="supplementary-material"}). The same analyses were carried out using only the Val103Ile carriers (n=8), because it has the higher frequency in our sample. The results showed that individuals carrying the missense mutation had lower median diastolic blood pressure (DBP) (73.0 \[68.0; 90.0\], n=7) when compared to noncarriers (89.0 \[81.0; 98.5\]; n=89) (*P*=0.020). Interestingly, a similar tendency was also observed in systolic blood pressure (SBP),, in which Val103Ile carriers (116.0 \[107.0; 140.0\], n=7) had lower median than noncarriers (135.0 \[121.5; 150.0\]; n=89) (*P*=0.065). This variant was also associated with hypertension (*P*=0.003). No differences were found between the groups in anthropometric and biochemical parameters ([Table S2](#SD2-dmso-12-257){ref-type="supplementary-material"}).

Phenotypic characterization of the Met1?, Ser36Thr, and Phe202Leu carriers
--------------------------------------------------------------------------

Met1? was identified in a 29-year-old female patient with childhood-onset obesity. On anthropometric examination, her current and maximum weight was 116.8 kg; height, 1.54 m; BMI, 49.2 kg/m^2^; waist circumference, 137 cm; hip circumference, 143 cm; WHR, 0.96; and neck circumference, 36.5 cm. Her blood pressure was 124/74 mm Hg. We also analyzed biochemical parameters. Her glucose was 86 mg/dL; TC, 182 mg/dL; HDL-c, 49 mg/dL; LDL-c, 115 mg/dL; and TGs, 91 mg/dL. Serum leptin, ghrelin, and insulin levels were 27.1 pg/mL, 18.9 pg/mL, and 13.1 mcU/mL, respectively. She did not exhibit any comorbidities associated with obesity, such as metabolic syndrome, hypertension, and type 2 diabetes mellitus. She did not take any medicine. The patient reported family history of obesity. Her older sister underwent the bariatric surgery. The patient presented a moderate binge-eating disorder (BED) and was physically inactive. According to 3-day dietary records, the patient has consumed a median of 4,900 calories per day, distributed as 36.24% carbohydrates, 20.86% proteins, and 42.90% total fats (27% saturated fatty acid and 700 mg cholesterol). She has consumed low quantity of vitamins and minerals, with exception for sodium (10 g).

Ser36Thr mutation was found in a 59-year-old female patient with childhood-onset obesity. On clinical examination, her current and maximum weight was 112.9 kg; height, 1.55 m; BMI, 47 kg/m^2^; waist circumference, 136 cm; hip circumference, 127.5 cm; WHR, 1.07; and neck circumference, 50 cm. The blood pressure was 147/86 mm Hg. We also obtained biochemical measurements, in which TC, 144 mg/dL; HDL-c, 38 mg/dL; LDL-c, 72 mg/dL; and TGs, 171 mg/dL. The patient exhibited type 2 diabetes mellitus, metabolic syndrome, and hypertension. She takes medicine to control blood pressure and glucose. The patient reported family history of obesity (mother and son).

We also detected the Phe202Leu variant in a 41-year-old male patient with early-onset obesity. His current weight was 127 kg; however, the maximum weight was 207 kg. His BMI was 40.1 kg/m^2^; waist circumference, 138 cm; hip circumference, 125 cm; and WHR, 1.10. The blood pressure was 140/100 mm Hg. The biochemical measurements were not available. The patient exhibited hypertension and reported family history of obesity (sibling).

Discussion
==========

The prevalence of obesity in Brazil has increased at alarming rates.[@b1-dmso-12-257] Common forms of obesity, which are found in most patients, are caused by interaction of environmental factors and genetic variants with minor effect. However, it has been characterized that single gene mutation can cause a rare form of nonsyndromic obesity in human, being the MC4R deficiency considered the most common form in general population.[@b5-dmso-12-257] Several rare variants were described in the coding region of *MC4R* gene, including deletions (n=6), frameshift (n=21), nonsense (n=24), and missense mutations (n=318).[@b9-dmso-12-257] Pathogenic mutations could lead to complete or partial loss of function, which may impair receptor signaling through intracellular retention of the protein, reduced ligand binding, or reduced downstream signaling.[@b9-dmso-12-257],[@b25-dmso-12-257],[@b26-dmso-12-257] In this present study, we aimed to investigate the prevalence of *MC4R* variants in a cohort of Brazilian patients. To our knowledge, this is the first study carrying a screening of the entire coding region of *MC4R* gene in our population.

As result, we identified five variants (Met1?, Ser36Thr, Val103Ile, Ile98=, and Phe202Leu) in our cohort of severely obese individuals, resulting in a carrier prevalence of 5.4%. Ser36Thr was found in one female patient with childhood-onset obesity (BMI: 47.0 kg/m^2^). Ser36Thr is located in the N-terminal domain of MC4R and was only found in obese individuals, suggesting a possible impact on MC4R functionality. Nevertheless, the effect of this variation on cAMP activity was shown to be neutral.[@b27-dmso-12-257],[@b28-dmso-12-257] We also detected the Phe202Leu variant in a male patient with childhood-onset obesity (BMI: 40.1 kg/m^2^). This variant is located in the fifth transmembrane domain of MC4R and was found in compound heterozygosity with Ile98=. Previous functional study showed that Phe202Leu decreased basal receptor activity.[@b29-dmso-12-257] In contrast, Xiang et al[@b30-dmso-12-257] reported that this variant has no effect on cell surface expression levels or MC4R activity. Additionally, Phe202Leu was found in both obese and nonobese subjects.[@b17-dmso-12-257],[@b29-dmso-12-257] The effect of these missense variants was classified as non-disease causing by in silico softwares. All these findings associated with our Bioinformatic analyses suggest that these two mutations are not associated with nonsyndromic monogenic obesity.

Interestingly, Val103Ile has been considered an obesity-protective polymorphism and was observed in both groups, being the most frequent variant identified in our sample (2.9%). This observation is similar to previous studies in a Polish cohort and a sample of the South American population.[@b17-dmso-12-257],[@b31-dmso-12-257],[@b32-dmso-12-257] Wang et al[@b31-dmso-12-257] have performed a meta-analysis using six East Asian studies, where they found that the frequency of this variant was 2.9% (n=19,882) in subjects with obesity and 3.9% (n=35,373) in nonobese individuals. Two previous functional analyses of MC4R harboring Val103Ile variant did not show a difference to the wild-type receptor.[@b33-dmso-12-257],[@b34-dmso-12-257] Nevertheless, Xiang et al[@b30-dmso-12-257] showed that the Val103Ile has a significant decrease in antagonist hAGRP potency when compared to MC4R wild type. Further functional analyses are necessary to investigate these divergent results.

The synonymous mutation (Ile198=) was identified in five individuals with childhood-onset obesity. The frequency of Ile198= was 1.59% in our sample. Hinney et al[@b18-dmso-12-257] found this variant in only one subject (0.2%) in a large German sample. Larsen et al[@b27-dmso-12-257] also reported that this mutation was identified in five different Danish patients with childhood-onset obesity (1.6%) and it was considered to possess normal receptor function.

We also identified a start codon lost variant (Met1?) in a 29-year-old woman, who developed obesity during childhood and her current BMI is 49.1 kg/m^2^. The patient exhibited a moderate BED and high calories consumed per day. Interestingly, Branson et al[@b35-dmso-12-257] have reported that BED is a major phenotype of *MC4R* mutation carriers. Bonnefond et al have also described that functional *MC4R* variant carriers presented higher prevalence of BED; however, this association was not observed in another study.[@b28-dmso-12-257],[@b36-dmso-12-257] This divergent result may be explained by inclusion sample criteria, since Hebebrand et al[@b36-dmso-12-257] selected individuals with common polymorphisms (V103I or I251L) and Bonnefond et al[@b28-dmso-12-257] selected participants with pathogenic mutations. Besides binge disorder, our patient did not present any other phenotypic abnormality, including hypertension. Her blood pressure levels were still lower than suggested for the new guideline.[@b23-dmso-12-257] We also examined her biochemical levels and found that her values of glucose, TGs, leptin, ghrelin, and insulin were lower than that observed in women with morbid obesity from Brazil.[@b21-dmso-12-257] We suggest a future study comparing this information with controls.

This mutation is located in the initiation codon ATG (c.1A\>G; Met1?), which may affect the translation process and impair the MC4R production. Our Bioinformatic analyses suggested that this variant disrupts the original ORF, resulting in a second ORF, which starts eight amino acids later. It is not clear whether this second ORF is functional resulting in a truncated receptor, because it would be necessary that all transcriptional and translation sequences and regulation work correctly. Further functional analyses are necessary to elucidate the impact of Met1? on MC4R.

Met1? is found in dbSNP database (<https://www.ncbi>. nlm.nih.gov/SNP/); however, it was not reported in any other study. This variant was absent in 1000 genome, EXAC database, predicted to be causative by at least one of the Bioinformatic tools and was interpreted to be pathogenic by current standards and guidelines.[@b24-dmso-12-257] Unfortunately, we were unable to evaluate the effect of this variant on the gene expression and the familial segregation. Collet et al[@b9-dmso-12-257] have also reported two complete loss-of-function mutations in the same codon (c.3G\>A and c.3G\>C; Met1Ile). None of the other previous described pathogenic mutations was identified in our sample.

The prevalence of pathogenic variants is consistent with earlier studies carried out in adult populations. For example, Jacobson et al[@b37-dmso-12-257] have screened the coding region of *MC4R* gene in Swedish sample and showed that the prevalence was 0.5%, being one of the lowest frequencies in Europe. They also did not find any of the previous reported null alleles. Most recently, Stanikova et al[@b38-dmso-12-257] identified two loss-of-function variants in obese Slovak children (0.7%). Interestingly, Lubrano-Berthelier et al[@b25-dmso-12-257] found a higher frequency of *MC4R* pathogenic mutations (2.6%) in French adult subjects with severe obesity. Tunç et al[@b6-dmso-12-257] also reported an elevated prevalence of *MC4R* mutations (8.5%) in obese children and adolescence from Turkey. These findings suggest that the high frequency of *MC4R* mutation associated with nonsyndromic monogenic obesity occurs only in certain ethnic groups.

Phenotypic characteristics were different among *MC4R* missense mutation carriers and noncarriers. Our study showed that the patients carrying the missense mutations (Ser36Thr, Val103Ile, and Phe202Leu) had higher median of WHR and lower prevalence of hypertension. Furthermore, Val103Ile carriers had lower median of DBP and the same tendency was also observed in SBP. This polymorphism was also negatively associated with hypertension, based on the new guideline.[@b23-dmso-12-257] Interestingly, previous functional studies indicated that Val103Ile has no implications on MC4R binding or signaling.[@b33-dmso-12-257] However, Rosmond et al[@b39-dmso-12-257] showed that heterozygous carriers of Val103Ile had lower WHR and trends for lower BMI when compared to noncarriers in a Swedish men cohort. Brönner et al[@b40-dmso-12-257] also reported that heterozygous carriers had lower TG levels in cardiovascular patients undergoing cardiac catheterization, suggesting that the Val103Ile polymorphism influences lipid metabolism in a Germany population. Heid et al[@b41-dmso-12-257] have analyzed a large cohort of German adults (7,888 participants) and found that the presence of isoleucine is associated with decreased waist circumference, decreased glycosylated hemoglobin, and increased HDL-c. They also observed that the Ile103 carriers have reduced risk of having three or more components of metabolic syndrome. Additionally, mutated allele has been negatively associated with obesity, which indicates a protective effect.[@b31-dmso-12-257] These findings suggest that Val103Ile might have a slight effect on metabolism without affecting the MC4R function in vitro.[@b27-dmso-12-257] Based on literature, we suggest that Val103Ile is negatively associated with hypertension due to protective effect on body weight and obesity. Our results suggest that blood pressure may be influenced in subjects carrying mutated allele; however, previous studies did not observe this relationship.[@b40-dmso-12-257],[@b41-dmso-12-257] Our findings showed a different result and the discrepancies may be explained by differences in genetic background and the sample criteria to select the participants. Further case--control studies with large cohort are necessary to confirm these results.

Conclusion
==========

In summary, our results showed for the first time the prevalence of variants in the coding region of *MC4R* in a cohort of Brazilian severely obese adults. Assessment of *MC4R* variants could be beneficial for future treatment strategies. Recently, an MC4R agonist (Setmelanotide) has shown to be effective in the treatment of obese patients with MC4R deficiency.[@b9-dmso-12-257] We identified five variants; one abolishes the normal translation initiation codon. It was found in a female patient with childhood-onset obesity (c.1A\>G; Met1?). Further functional or expression analyses are necessary to confirm the pathogenicity of this variant. We also observed significant phenotypic differences among missense variant carriers and noncarriers, suggesting that *MC4R* genetic variations may impact body fat distribution and blood pressure.

Supplementary materials
=======================

###### 

Primers used to amplify the coding region of MC4R

  Primers          Sequence
  ---------------- ------------------------------
  MC4RI forward    5′-TCAAGCTCTGGACTTGTGACAT-3′
  MC4RI reverse    5′-CCAACCCGCTTAACTGTCAT-3′
  MC4RII forward   5′-TTTCAATTGCAGTGGACAGG-3′
  MC4RII reverse   5′-ACGGAAGAGAAAGCTGTTGC-3′

###### 

Influence of *MC4R* mutations on anthropometric, biochemical, and pressure parameters

  Variables                                                 Missense mutations (Ser36Thr, Val103Ile, and Phe202Leu)   Mutation Val103Ile                                                                                                        
  --------------------------------------------------------- --------------------------------------------------------- ---------------------- ----------- ---------------------- ------- ----- ---------------------- --- ---------------------- -------
  Weight (kg)                                               147                                                       134.5 (117.8; 151.0)   10          129.2 (115.8; 180.1)   0.951   149   134.0 (117.5; 151.0)   8   134.5 (117.1; 181.5)   0.632
  Height (m)                                                147                                                       1.64 (1.58; 1.71)      10          1.58 (1.54; 1.76)      0.414   149   1.64 (1.58; 1.71)      8   1.58 (1.55; 1.73)      0.369
  BMI (kg/m^2^)                                             147                                                       48.9 (44.3; 55.0)      10          48.2 (42.9; 57.8)      0.812   149   48.9 (44.2; 54.9)      8   51.8 (44.0; 63.3)      0.332
  Waist circumference (cm)                                  146                                                       141.5 (128.9; 150.2)   10          138.0 (135.2; 163.5)   0.595   148   140.5 (129.2; 150.0)   8   139.5 (134.0; 166.5)   0.412
  Hip circumference (cm)                                    146                                                       145.0 (135.9; 154.0)   10          142.0 (126.9; 160.0)   0.534   148   144.5 (135.1; 153.7)   8   146.0 (131.2; 169.5)   0.667
  WHR                                                       146                                                       0.97 (0.92; 1.0)       10          0.99 (0.96; 1.05)      0.048   148   0.97 (0.92; 1.00)      8   0.97 (0.96; 1.03)      0.283
  SBP                                                       87                                                        134.0 (121.0; 150.0)   9           124.0 (108.5; 143.5)   0.189   89    135.0 (121.5; 150.0)   7   116.0 (107; 140.0)     0.063
  DBP                                                       87                                                        89.0 (81.0; 98.0)      9           74.0 (69.0; 91.0)      0.079   89    89.0 (81.0; 98.5)      7   73.0 (68.0; 90.0)      0.020
  Glucose                                                   106                                                       97.0 (90.0; 109.0)     4           99.0 (86.5; 168.5)     0.987   106   97.0 (90.0; 109.0)     4   99.0 (86.5; 168.5)     0.987
  Cholesterol total                                         121                                                       192.0 (165.5; 220.0)   5           168.0 (154.0; 192.5)   0.209   122   191.0 (164.5; 220.0)   4   175.0 (165.0; 197.7)   0.487
  HDL-cholesterol                                           121                                                       46.0 (41.0; 53.0)      5           43.0 (36.0; 48.5)      0.245   122   46.0 (41.0; 53.0)      4   45.5 (36.2; 48.7)      0.469
  LDL-cholesterol                                           117                                                       116.0 (95.0; 134.0)    5           109.0 (84.0; 130.0)    0.514   118   116.0 (94.5; 133.5)    4   112.0 (99.2; 137.5)    0.966
  Triglycerides                                             121                                                       127.0 (94.5; 167.0)    5           99.0 (84.0; 148.0)     0.368   122   128.0 (95.2; 168.7)    4   95.0 (80.5; 118.5)     0.140
  Hemoglobin                                                90                                                        5.6 (5.0; 6.3)         3           6.3 (6.3)              0.104   81    5.6 (5.0; 6.4)         2   6.3 (6.3; 6.3)         0.281
  CRP                                                       89                                                        1.11 (0.65; 1.63)      3           2.99 (0.51)            0.296   90    1.12 (0.65; 1.65)      2   1.75 (0.51)            0.843
  Hypertension[a](#tfn8-dmso-12-257){ref-type="table-fn"}                                                                                                                                                                                       
   Yes                                                      147                                                       105 (71.4)             10          6 (60)                 0.442   149   107 (71.8)             8   4 (50)                 0.187
   No                                                       42 (28.6)                                                 4 (40)                 42 (28.2)   4 (50)                                                                                 
  Hypertension[b](#tfn9-dmso-12-257){ref-type="table-fn"}                                                                                                                                                                                       
   Yes                                                      147                                                       129 (87.8)             10          6 (60)                 0.014   149   131 (88)               8   4 (50)                 0.003
   No                                                       18 (12.2)                                                 4 (40)                 18 (12)     4 (50)                                                                                 

**Notes:** Data are presented as median values (IQR 25%--75%) for quantitative traits and n (%) for qualitative traits. Data were analyzed by Mann--Whitney test (for non-normally distributed variables) or χ^2^ test (for categorical variables).

Hypertension -- based on blood pressure ≥140 × 90 mm Hg.

Hypertension -- based on blood pressure ≥130 × 80 mm Hg.

*P*-value for differences between mutated and nonmutated subjects.

**Abbreviations:** BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; HDL-cholesterol, high-density lipoprotein-cholesterol; LDL-cholesterol, low-density lipoprotein-cholesterol; SBP, systolic blood pressure; WHR, waist--hip ratio.
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###### 

Clinical characterization of the study participants from Brazilian cohort

  Parameters                                                n            All                    n           Childhood-onset obesity   N    Adolescence/youth-onset obesity   *P*-value*[\*](#tfn4-dmso-12-257){ref-type="table-fn"}*
  --------------------------------------------------------- ------------ ---------------------- ----------- ------------------------- ---- --------------------------------- ---------------------------------------------------------
  Age (years)                                               157          36 (28; 43)            97          37.0 (28; 43)             60   36 (28; 42)                       0.750
  Gender                                                                                                                                                                     
   Female                                                   157          121 (77.1)             97          73 (75.3)                 60   48 (80.0)                         0.492
   Male                                                     36 (22.9)    24 (24.7)              12 (20.0)                                                                    
  Ethnicity                                                                                                                                                                  
   Caucasian                                                157          56 (35.7)              97          34 (35.1)                 60   22 (36.7)                         0.837
   Non-Caucasian                                            101 (64.3)   63 (64.9)              38 (63.3)                                                                    
  Weight (kg)                                               157          134.0 (117.5; 151.5)   97          133.5 (118.0; 151.0)      60   135.0 (113.1; 163.3)              0.798
  Height (m)                                                157          1.64 (1.58; 1.71)      97          1.64 (1.58; 1.72)         60   1.63 (1.58; 1.70)                 0.931
  BMI (kg/m^2^)                                             157          48.9 (44.2; 55.0)      97          48.7 (44.9; 53.6)         60   49.8 (42.8; 56.1)                 0.546
  Waist circumference (cm)                                  156          140.5 (130.0; 150.7)   97          138.5 (130.0; 148.0)      59   142.0 (128.5; 153.0)              0.600
  Hip circumference (cm)                                    156          144.5 (135.1; 154.1)   97          143.0 (134.7; 152.0)      59   147.0 (137.0; 156.0)              0.308
  WHR                                                       156          0.97 (0.92; 1.01)      97          0.98 (0.92; 1.01)         59   0.96 (0.92; 1.00)                 0.257
  SBP                                                       96           133.5 (120.2; 149.0)   58          132.0 (120.7; 149.2)      38   137.5 (118.5; 149.7)              0.787
  DBP                                                       96           88.5 (79.2; 97.7)      58          88.5 (80.7; 98.2)         38   88.5 (76.7; 95.7)                 0.639
  Glucose                                                   110          97.0 (90.0; 109.0)     65          98.0 (92.0; 108.0)        45   96.0 (88.5; 113.0)                0.872
  Cholesterol total                                         126          189.5 (164.7; 218.0)   75          192.0 (163.0; 225.0)      51   184.0 (165.0; 212.0)              0.276
  HDL-cholesterol                                           126          46.0 (41.0; 53.0)      75          45.0 (40.0; 53.0)         51   48.0 (42.0; 54.0)                 0.288
  LDL-cholesterol                                           122          115.5 (95.5; 133.5)    72          119.5 (95.5; 143.0)       50   109.5 (92.7; 126.5)               0.121
  Triglycerides                                             126          125.5 (93.0; 166.5)    75          131.0 (93.0; 175.0)       51   120.0 (93.0; 136.0)               0.143
  Hemoglobin                                                93           5.7 (5.0; 6.3)         58          5.65 (4.9; 6.5)           35   5.7 (5.1; 6.2)                    0.809
  CRP                                                       92           1.12 (0.64; 1.66)      58          1.08 (0.56; 1.64)         34   1.12 (0.71; 1.73)                 0.622
  Hypertension[a](#tfn2-dmso-12-257){ref-type="table-fn"}                                                                                                                    
   Yes                                                      157          111 (70.7)             97          70 (72.2)                 60   41 (68.3)                         0.608
   No                                                       46 (29.3)    27 (27.8)              19 (31.7)                                                                    
  Hypertension[b](#tfn3-dmso-12-257){ref-type="table-fn"}                                                                                                                    
   Yes                                                      157          135 (86)               97          86 (88.7)                 60   49 (81.7)                         0.220
   No                                                       22 (14)      11 (11.3)              11 (18.3)                                                                    

**Notes:** Data are presented as median values (IQR 25%--75%) for continuous traits and n (%) for categorical traits. Data were analyzed by Mann--Whitney test (for non-normally distributed variables) or chi-squared test (for categorical variables).

Hypertension -- based on blood pressure ≥140 × 90 mm Hg.

Hypertension -- based on blood pressure ≥130 × 80 mm Hg.

*P*-value for differences between case and control subjects.

**Abbreviations:** BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; HDL-cholesterol, high-density lipoprotein-cholesterol; LDL-cholesterol, low-density lipoprotein-cholesterol; SBP, systolic blood pressure; WHR, waist--hip ratio.

###### 

Identified variants in the coding region of *MC4R* gene

  Mutation protein   cDNA        ID             Type         Polyphen   SIFT          Clinical significance       No. of carriers   Allele frequency (%)   Onset of obesity
  ------------------ ----------- -------------- ------------ ---------- ------------- --------------------------- ----------------- ---------------------- -----------------------------
  Met1?              c.1A\>G     rs1356972268   Start lost   Benign     Deleterious   NA                          1                 0.32                   Childhood
  Ser36Thr           c.106T\>A   rs954123325    Missense     Benign     Tolerated     NA                          1                 0.32                   Childhood
  Val103Ile          c.307G\>A   rs2229616      Missense     Benign     Tolerated     Likely benign, protective   8                 2.87                   Childhood/adolescence/youth
  Phe202Leu          c.606C\>A   rs138281308    Missense     Benign     Tolerated     Uncertain significance      1                 0.32                   Childhood
  p.Ile198=          c.594C\>T   rs61741819     Synonymous   NA         NA            With likely benign allele   5                 1.59                   Childhood

**Abbreviations:** NA, not available; SIFT, Sorting Intolerant From Tolerant.
